The blood-brain barrier (BBB) limits brain uptake of therapeutic antibodies. It is believed that the BBB is disrupted in Alzheimer's disease (AD), potentially increasing drug permeability de facto. Here we compared active versus passive brain uptake of systemically dosed antibodies (anti-transferrin receptor [TfR] bispecific versus control antibody) in mouse models of AD. We first confirmed BBB disruption in a mouse model of multiple sclerosis as a positive control. Importantly, we found that BBB permeability was vastly spared in mouse models of AD, including PS2-APP, Tau transgenics, and APOE4 knockin mice. Brain levels of TfR in mouse models or in human cases of AD resembled controls, suggesting target engagement of TfR bispecific is not limited. Furthermore, infarcts from human AD brain showed similar occurrences compared to age-matched controls. These results question the widely held view that the BBB is largely disrupted in AD, raising concern about assumptions of drug permeability in disease.
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It is generally believed that neurodegeneration is accompanied by BBB dysfunction, potentially increasing drug bioavailability in the CNS. Bien-Ly et al. report that AD mouse models lack widespread BBB disruption and display restricted passive permeability to therapeutic antibodies.
INTRODUCTION
The extent of BBB impairment in neurodegenerative disease and how it affects the bioavailability of therapeutics remains unclear. Focusing on AD, the assessment of BBB disruption has been described using various methods (Nicolakakis and Hamel, 2011; Erickson and Banks, 2013) . Studies in AD mouse models suggest that the greatest determinant of altered cerebrovascular function and BBB disruption is vascular amyloid deposition (Han et al., 2008; Maier et al., 2014) , which may lead to localized transient BBB disruption. In fact, cerebrovascular lesions were more frequently observed in post-mortem AD cases with coincident cerebrovascular amyloid angiopathy (De Reuck, 2012) . However, BBB impairments may exist in non-amyloid-depositing AD models such as APOE4 mice (Bell et al., 2012) or mutant human tau transgenic mice (Blair et al., 2015) .
We investigated the extent of BBB breakdown across multiple AD mouse models, focusing on determining brain penetrance of therapeutic antibodies. We used anti-TfR/BACE1 versus anti-BACE1 and control antibody to compare active brain uptake versus passive IgG leakage (Yu et al., 2011; Couch et al., 2013) . We first assessed a model of multiple sclerosis with reported BBB and blood-spinal cord barrier (BSCB) disruption (Bennett et al., 2010) and observed extensive barrier permeability to IgG. In contrast, minimal BBB disruption was detected in PS2-APP transgenic mice, human Tau P301L and P301S mutant mice, and mice lacking APOE or expressing human APOE4. We also found that TfR levels were unaltered in these AD models and in human AD post-mortem samples compared to controls, suggesting brain uptake of TfR-based therapeutics may be unimpaired. These findings, combined with an extensive analysis of brain infarcts in age-matched control and AD samples, indicate a lack of widespread BBB disruption in AD and further support the need for an enhanced BBB-crossing therapeutic delivery platform.
RESULTS

Detection of BBB Antibody Permeability in EAE-Induced Mice
To establish a BBB antibody permeability assessment paradigm, we utilized a disease model with BSCB disruption and evidence of BBB leakage. Mice were induced to develop experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis (MS). At peak disease onset (15 days post-inoculation), naive and EAE-induced mice were intravenously (i.v.) injected with 25 mg/kg of control IgG (Con IgG), anti-BACE1, or anti-TfR D /BACE1 ( Figure 1A ). We reasoned that BBB disruption would allow passive entry of significantly more antibody into the Spinal Cord
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n E.2 n E.4 n E.4 n E.4 n E.3 n E.2 n E.3 n E.4 n E.1 n n E.4 n E.4 n E.4 n E.4 n E.2 (Yu et al., 2011; Couch et al., 2013) was similar to or exceeded the passive entry of Con IgG or anti-BACE1 due to BBB disruption. All antibodies were on a human IgG1 backbone, allowing for sensitive measurements of drug concentrations in mouse brain by a human IgG Fc-specific ELISA. Dosing with anti-BACE1 or anti-TfR D / BACE1 also enabled assessment of target engagement (i.e., BACE1 inhibition) by measuring amyloid-b (Ab) concentrations from brain lysates. After 24 hr, we extensively perfused the mice to remove circulating vascular IgG and measured antibody levels in cortex (includes hippocampus), cerebellum, and spinal cord lysates. We observed 3-fold more Con IgG and anti-BACE1 in the cortex of EAE-induced animals compared to naive mice, 5-to 10-fold more in cerebellum, and up to 80-fold more antibody in diseased spinal cord ( Figures 1B-1D ). Importantly, levels of anti-TfR D /BACE1 were not significantly different between EAE and naive mice in all regions, were 10-fold higher compared to Con IgG in naive mice, and were 2-to 3-fold higher than levels of Con IgG in the cortex and cerebellum of EAE mice. These findings demonstrate that TfR bispecific antibodies penetrate the BBB and actively access the cortex to a greater extent than non-targeting IgGs, regardless of disease state or subsequent barrier disruption. Spinal cord displayed more Con IgG and anti-BACE1 in EAE mice than TfR bispecific, suggesting greater barrier dysfunction and antibody penetrance in this tissue during peak disease onset that exceeds TfR-mediated antibody uptake.
We next assessed the potential leakage of endogenous mouse IgG and serum albumin into brain by western blot analysis of cortex (Figures 1E and 1F) , cerebellum ( Figure 1G ), and spinal cord lysates ( Figure 1H ). We detected significantly increased levels of extravasated IgG ( Figures 1F-1H ) and albumin (Figures S1A-S1D) in EAE mice compared to naive controls. These EAE-induced increases in plasma proteins were not accompanied by changes in the tight junction protein claudin-5 (Figures S1A-S1C and S1E), suggesting barrier leakage was not due to degradation of junctional components. We also observed increased TfR levels in EAE brains and a reduction in spinal cord ( Figure S1F ). The increased TfR may contribute to the slight elevation of TfR bispecific levels detected in EAE brain samples (Figures 1B and 1C) , suggesting greater brain uptake with higher TfR expression. Alternatively, the slight increases in anti-TfR D /BACE1 in EAE mice may also be attributed to BBB disruption due to underlying inflammation, enabling additional passive antibody diffusion, especially in spinal cord ( Figure 1D ). We also assessed Ab 40 concentrations and found that mice treated with TfR bispecific, either naive or EAE-induced, had overall decreased Ab 40 compared to those treated with Con IgG or anti-BACE1 (Figures S1G-S1I), indicating that the mice with higher brain antibody levels displayed greater Ab reductions.
Lack of Widespread BBB Permeability in Aged PS2-APP Mice
We first employed a sensitive radiolabeled tracer technique (Boswell et al., 2012) to explore the overall extent of BBB permeability in the PS2-APP line of transgenic mice, a well-characterized preclinical AD model with age-related amyloid pathology (Grueninger et al., 2010) . Molecules of various molecular weights (3 kDa dextran, 67 kDa albumin, and 150 kDa Con IgG) were radioiodinated, and their CNS levels were assessed at appropriate time points after trace-dosing in young (5-6 month, limited plaque deposition) and aged (15-16 month, extensive plaque burden) PS2-APP and wild-type (WT) littermate controls. An additional group of 5-month-old WT mice were LPS-injected 6 hr before trace-dosing to serve as a model with reported BBB disruption (Takeda et al., 2013) . Surprisingly, we did not detect differences in the levels of any radiotracers between the PS2-APP mice, young or aged, versus WT (Figures 2A-2D ). Due to the high sensitivity of this assay, this negative finding strongly suggests a lack of subtle BBB impairments in the PS2-APP mice, despite significant amyloid pathology at advanced ages (Grueninger et al., 2010) . In addition, only 3 kDa 125 I-Dextran had significantly greater brain uptake in LPS-injected animals ( Figure 2A ), demonstrating that LPSinduced peripheral inflammation impairs the BBB only to the extent of rendering permeability to molecules between 3 kDa and possibly up to 67 kDa. We also found that brain uptake of the radioprobe 86 Rb + (rubidium-86, an 86-dalton cation injected as RbCl that does not cross the intact BBB due to hydrophilicity and charge), was not significantly different between WT controls versus young and aged-matched PS2-APP and LPS-injected mice ( Figure 2D ). These findings indicate that other properties of a molecule beyond its molecular weight, such as ionic charge, may restrict its barrier permeability.
We next dosed PS2-APP mice, aged 10-13 months, with Con IgG, anti-BACE1, or anti-TfR D /BACE1 at 25 mg/kg. At 24 hr postdose, cortical levels of Con IgG and anti-BACE1 were similar between PS2-APP and WT littermates ( Figure 2E ), suggesting an absence of barrier leakage or non-specific passage of i.v.-administered IgG through the BBB. Conversely, anti-TfR D / BACE1 levels were 4-to 6-fold greater in both genotypes compared to Con IgG and anti-BACE1, supporting robust TfRmediated, active brain uptake. Similar results were obtained with younger PS2-APP mice (aged 5 months; Figure 2F ). To determine if endogenous mouse IgG and albumin extravasation was also chronically increased in PS2-APP mice, we probed brain lysates from the aged ( Figure 2G ) and young (not shown) cohorts by western blot. We found the levels of mouse IgG and albumin were similar between WT and PS2-APP mice ( Figures 2H and 2I) . Additionally, claudin-5 and TfR were not altered in the transgenic mice ( Figures 2J and 2K ). These data, combined with the radiotracer observations, further indicate that the BBB of aged, amyloid-laden PS2-APP mice is otherwise intact and restricts passive brain uptake of antibody. we assessed brain uptake of Con IgG, anti-BACE1, or anti-TfR D / BACE1 at 24 hr (25 mg/kg dose) in transgenic mice expressing human Tau P301L aged 14-18 months or Tau P301S aged 8-10 months. The tauopathy and neurodegenerative phenotype in line P301L occurs at later ages (Terwel et al., 2005) , while P301S mice display prominent neurodegeneration by 9 months (Yoshiyama et al., 2007) . Analysis of brain antibody levels from both P301L-and P301S-dosed mice ( Figures 3A and 3B ) revealed no differences in passive antibody uptake for Con IgG and anti-BACE1 compared to WT littermates, with levels at 2-3 nM. We observed a slight but significant reduction in anti-BACE1 levels in P301L cortex ( Figure 3A , p = 0.02). Because prior studies have reported that the cerebellum BBB is more leaky (Phares et al., 2006; Hafezi-Moghadam et al., 2007) , we specifically assessed its antibody uptake in P301S mice and observed no differences from WT ( Figure 3C ). In both tau lines, brain uptake of anti-TfR D /BACE1 did not differ between genotypes, and was significantly greater than Con IgG and anti-BACE1, confirming that TfR-mediated transcytosis through the BBB improves brain uptake.
We next assessed BBB antibody permeability in APOE knockout (EKO) mice and in APOE4 knockin (E4KI) mice at 2-3 months, the age at which BBB impairment was previously shown (Hafezi-Moghadam et al., 2007; Bell et al., 2012) . We observed that cortical levels of Con IgG and anti-BACE1 in these lines also did not differ significantly from WT controls ( Figure 3D ). Conversely, levels of anti-TfR D /BACE1 were 7-to 10-fold greater in all three lines. Significantly more TfR bispecific was observed in EKO and E4KI cortex over WT; however, the effect size of the difference was negligible. Because we failed to observe significant increases in control antibodies in the EKO or E4KI mice, we used the radiotracer assay to further probe for subtle BBB 
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[Antibody] nM disruption in similarly aged EKO mice. Compared to WT controls, we found that overall, EKO mice did not have significantly more 3 kDa dextran, 10 kDa dextran, Con IgG, RbCl, or labeled RBCs in the CNS tissues sampled ( Figure S2 ).
We also examined cortex and spinal cord of therapeutically dosed SOD1
G93A mutant mice, a model of familial amyotrophic lateral sclerosis, at peak onset of motor symptoms (14 weeks). We observed restricted access of Con IgG and anti-BACE1 in the transgenic mice and significantly greater uptake of TfR bispecific ( Figures 3E and 3F ).
All mice were extensively perfused in therapeutic dosing studies prior to tissue collection to ensure complete removal of dosed antibody from the vasculature and to prevent overestimation of antibody levels. Plasma antibody concentrations from all cohorts of therapeutically dosed mice showed no significant differences between disease and non-diseased genotypes (data not shown). These findings, combined with the overall lack of differences in brain antibody levels, suggest that the ratio of IgG in brain to blood is not significantly affected by possible underlying neuropathology. We further confirmed antibody uptake into brain parenchyma by assessing Ab 40 concentrations. Overall, animals dosed with TfR bispecific had significantly reduced Ab levels in cortex compared to Con IgG or anti-BACE1, indicating efficient antibody uptake in brain (Figures S3A-S3F ). We only analyzed rodent Ab 40 in the WT littermates of the PS2-APP mice ( Figures S3A and S3B ) because transgene expression of human Swedish mutant APP precludes BACE1 inhibition . Also, contributions to Ab reductions from the brain vasculature are minimal due to low expression of BACE1 by brain endothelial cells .
Incidence of Brain Infarcts in Human AD Samples Resembles Controls
We next examined a large cohort of post-mortem human tissue from AD patients (n = 561) and age-matched controls (n = 227) to determine whether there were differences in the number and size of brain infarcts that may represent evidence of localized BBB disruption and permeability. Patients with severe cerebrovascular disease, vascular dementia, or history of stroke were excluded from the final dataset (Beach et al., 2015) . The total percentage of brain infarcts was similar between AD and control samples and remained similar in specific CNS subregions (Table 1) . In both AD and controls, most brain infarcts analyzed were classified as microinfarcts based on size, and no differences were found in the percentage of samples with various sized infarcts (Table 1) . Infarct volume in all brain areas or only cortical tissue was also similar in AD and controls ( Figures  4A, 4B, and S4A-S4C ). AD and control samples were further categorized based on plaque scores, and no differences in median infarct volumes between the two groups were identified ( Figure 4C ). These findings suggest that contributions to BBB impairment and leakiness from brain infarcts are not associated with disease status and may be a common occurrence with age.
Cortical TfR Levels Are Not Decreased in AD We next assessed TfR levels in brain lysates prepared from a separate cohort of human AD post-mortem tissue. We probed superior frontal gyrus (SFG) and entorhinal cortex of agematched controls, early AD, and confirmed AD samples and detected no differences in TfR levels ( Figures 4D-4F ). Claudin-5 levels were also not altered between AD and controls (not shown), while levels of neurofibrillary tau, detected by anti-PHF-1, confirmed disease status ( Figure 4D ). We probed brain lysates from PS2-APP ( Figure 2F ), Tau P301L ( Figures S5A and  S5B ), or P301S ( Figures S5C and S5D ) mice used in our dosing studies and observed similar TfR levels as WT littermates. Levels of TfR resembled WT mice in aged human APOE knockin lines and EKO mice ( Figures S5E and S5F ) and in diseased SOD1 G93A transgenic mice (Figures S5G and S5H ). These data provide evidence that TfR levels in brain are not reduced, thus not limiting target engagement of TfR-based therapeutics.
DISCUSSION
It is generally believed that the compromised BBB of Alzheimer's patients and mouse models accelerates disease onset or progression and may also increase therapeutic penetrance into the CNS. Our results show that antibodies do not demonstrate increased passage into the brain in multiple preclinical models of AD, and that brain infarct number and size are similar in AD patients as controls, which opposes the idea of widespread BBB disruption in AD. We used two quantitative experimental approaches to measure BBB permeability, a therapeutic antibody-dosing paradigm and a sensitive radiotracer assay with multiple-sized molecular probes. We observed that in the context of clear BBB disruption in EAE mice, dosed antibodies showed robust CNS permeability. The amounts of the radiotracers and antibodies we detected in brain were very low; however, the absolute quantifications were above the level of detection, raising the important and underappreciated point that most molecules, regardless of molecular weight, cross the healthy BBB, including therapeutic antibodies (Yu and Watts, 2013) . Thus, the ability to measure baseline levels of compounds in brain enabled us to compare brain uptake of tracer and therapeutically dosed antibody levels between genotypes in our studies. No differences were observed in levels of endogenous mouse IgG, albumin, or claudin-5 in the AD transgenic mice compared to controls, indicating a lack of chronic BBB disruption. Moreover, levels of TfR were not decreased in AD models and in samples from AD patients, therefore maintaining the accessibility of an anti-TfR-based therapeutic. The various methods historically used to assess BBB dysfunction in AD patients, post-mortem samples, or in mouse models have led to many disparate findings. Early studies via DCE-MRI showed no difference between AD patients or age-matched controls (Schlageter et al., 1987) . More recent data have reported decreased blood flow in AD cases (Bateman et al., 2006; Hanyu et al., 2010) and age-dependent BBB breakdown in MCI patients, with the cortex remaining largely spared (Montagne et al., 2015) . Our finding that the number and size of cortical microinfarcts is similar between controls and diseased samples is aligned with some of these observations and other histological findings (Del Ser et al., 2005) . A caveat of this approach is the potential underestimation of BBB impairment by not accounting for non-infarct associated disruption. Other studies have reported increased incidence of microbleeds or vascular lesions in AD cases possibly due to comorbid cerebrovascular vascular dementia or small vessel disease (SVD), which were not increased in pure AD cases alone (De Reuck, 2012; Toledo et al., 2013) . As such, we excluded these cases in our infarct assessments. Cerebrovascular lesions are a common observation in most aged control samples (Farrall and Wardlaw, 2009; Bridges et al., 2014) , with old infarcts occurring in 43% of elderly brains in the Banner Brain Donation Program from which our dataset and samples were sourced (Beach et al., 2015) .
The transgenic PS2-APP mice utilized in our studies have extensive parenchymal amyloid and restricted vascular amyloid on surface meningeal vessels (Grueninger et al., 2010) , allowing us to test if parenchymal plaque alters BBB integrity. Nevertheless, studies in mice and humans show a relationship between cerebrovascular amyloid angiopathy (CAA) and BBB dysfunction or microhemorrhages (Han et al., 2008; Maier et al., 2014; Attems, 2005) . Thus, additional studies comparing passive brain uptake of antibodies in APP transgenic mice with and without CAA are warranted. Recent data have shown that the cerebrovascular volume of APP-PS1 mice (no CAA) is unperturbed with age (Do et al., 2014) . Using a chronic i.v. IgG dosing strategy, this group also found that aged 3xTg-AD and E4KI mice did not have greater IgG accumulation in brain versus controls (St-Amour et al., 2013; Alata et al., 2015) . These studies support our findings regarding a lack of widespread BBB permeability to IgG, notably in a different AD model.
Overall, our results demonstrate that the BBB remains intact in multiple preclinical models of AD. These findings further support strategies aimed at utilizing TfR-mediated brain uptake as a viable approach to opening up the CNS to antibody therapeutics in neurodegenerative disease, particularly in Alzheimer's disease. 
EXPERIMENTAL PROCEDURES
